PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY

▴ PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla

Pfizer Inc. and BioNTech today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. 

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.

Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

Tags : #LatestPharmaNewsNov9 #LatestPfizerNewsNov9 #TreatmentforCOVID19 #TreatmentforCoronavirus

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Your Screen Addiction is Shaping Your Child’s Digital Future But Not in a Good WayFebruary 12, 2025
Your Screen Addiction is Shaping Your Child’s Digital Future But Not in a Good WayFebruary 12, 2025
Sarvodaya Hospital Champions Epilepsy Awareness on International Epilepsy DayFebruary 12, 2025
The Oxygen Crisis: Why 5 Billion People Are Struggling to BreatheFebruary 12, 2025
SDGs warrant breakthroughs not breakdowns in development financingFebruary 11, 2025
Emotional and Mental Overload in the AI Era? Meditation is Your CoPilot to Clarity and Calm! says DaajiFebruary 11, 2025
Avvatar Creatine Monohydrate Achieves Trustified Gold CertificationFebruary 11, 2025
Bengaluru’s Pet Healthcare Gets a Boost with Supertails’ Offline ExpansionFebruary 11, 2025
Can Classical Music Shape a Baby’s Heartbeat Before Birth? A New Study Says YesFebruary 11, 2025
What If Learning Was Like Weightlifting? New Science Says It Is!February 11, 2025
Medanta organizes ‘Catwalk for Cancer’ to honour survivors’ strength and resilienceFebruary 10, 2025
Defence Minister, Shri. Rajnath Singh applauds the work done by Aero A2Z for manifesting ‘Make in India’ radar systems February 10, 2025
6 Things Every Young Woman Should Know About Reproductive HealthFebruary 10, 2025
Special Story on Epilepsy DayFebruary 10, 2025
Right wing policies threaten gender equality and health securityFebruary 10, 2025
Lumpy Skin Disease Wiped Out 200,000 Cattle: Can This New Vaccine Be The Ultimate Solution?February 10, 2025
The Future of Healthcare: A Self-Powered Sensor That Tracks Wound Healing Like Never BeforeFebruary 10, 2025
Deworming in Children: A Crucial Step Towards Healthy GrowthFebruary 07, 2025
AI-powered blue-collar hiring platform Vahan.ai secures investment from APAC HR services leader Persol Group amid booming gig economy in India; plans to develop AI recruitment technology to support 8 major Indian languages February 07, 2025
Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025